Eli Lilly is betting big on the future of psychedelic-inspired mental health treatments, announcing a deal to acquire clinical-stage biotech AtaiBeckley in a transaction valued at up to $3.8 billion.

 

The acquisition strengthens Lilly's neuroscience pipeline with experimental therapies targeting treatment-resistant depression (TRD), a condition affecting millions of people who have failed to respond to existing antidepressants.

 

At the center of the deal is BPL-003, an intranasal synthetic form of 5-MeO-DMT designed to deliver rapid and long-lasting relief from treatment-resistant depression. 

 

The therapy has received FDA Breakthrough Therapy Designation, has begun Phase 3 activities, and showed promising Phase 2b results, with patients experiencing rapid reductions in depressive symptoms after an in-clinic treatment lasting about two hours on average. The benefits persisted for months.

 

Lilly will also gain VLS-01, a buccal film formulation of DMT currently in Phase 2b testing, along with AtaiBeckley's broader pipeline of next-generation neuroplastogens aimed at restoring the brain's ability to form new neural connections.

 

Unlike conventional antidepressants, which primarily alter neurotransmitter levels, AtaiBeckley's therapies are designed to restore synaptic connectivity—a biological mechanism increasingly believed to play a key role in treatment-resistant depression and other severe psychiatric disorders.

 

"Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, executive vice president and president, Lilly Neuroscience. "Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."

 

The companies say the acquisition reflects growing confidence that neuroplastogen-based therapies could reshape treatment for some of the most difficult mental health conditions.

 

"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," said Srinivas Rao, co-founder and chief executive officer of AtaiBeckley. "Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."

 

AtaiBeckley founder and chairman Christian Angermayer said Lilly's global scale would help bring the company's pipeline to patients more quickly.

 

"From Atai's founding, our mission has been to bring transformative mental health treatments to the patients who need them most. Joining Lilly gives this pipeline, and the patients waiting for it, the benefit of the resources and scale Lilly has to potentially advance therapies faster than we could alone. I am confident this transaction represents the best path forward for patients and shareholders," said Angermayer.